Supreme Court declines plea to make nucleic acid tests compulsory at blood banks

NAT tests are more expensive but more accurate in detecting HIV, Hepatitis B, C viruses in the blood; petitioner sought to protect thalassemia patients who require frequent blood transfusions and are at risk from infected blood

Updated - March 13, 2026 09:58 pm IST - NEW DELHI

The Supreme Court of India. File picture

The Supreme Court of India. File picture | Photo Credit: PTI

The Supreme Court on Friday (March 13, 2026) refused to direct the government to compulsorily conduct “expensive” Nucleic Acid Tests (NAT) to identify diseases ahead of blood transfusions, saying that it does not have specialised knowledge about either medical science or the costs involved.

A Bench headed by Chief Justice of India Surya Kant pointed out that States have their financial limitations, and the judges cannot “pretend to understand medical science” to pass judicial orders making NAT mandatory.

The Bench gave the petitioner — the Sarvesham Mangalam Foundation, represented by advocate A. Velan —liberty to make comprehensive representations to the Health Secretaries of States, “who may, with the aid and advice of domain experts, take appropriate decisions” on the issue.

‘No ulterior motives’

The hearing saw the court repeatedly question the intentions of the NGO in filing the petition. At one point, the Bench asked Mr. Velan, “Do you think PILs are not funded from abroad, do you think so?”

Mr. Velan responded that the petitioner had no ulterior motives, and had only sought to highlight the case of thalassemia patients who require frequent blood transfusion and were vulnerable to the transfusion of infected blood. The petition described such medical mishaps as “preventable tragedies”.

Invoking right to life

NAT is a highly sensitive molecular technique that detects the genetic material of viruses like HIV, Hepatitis B, and Hepatitis C in the blood. In a previous hearing, the court had asked the petitioner to provide more details about the cost-effectiveness of NAT compared to the more commonly used Enzyme-Linked Immunosorbent Assay (ELISA) test. The Chief Justice had questioned if all the States could afford NAT in government blood banks and hospitals.

The petitioner had argued that the right to safe blood transfusion was a fundamental part of the right to life under Article 21 of the Constitution.

The case had gained significance in the context of at least six children reported to be HIV positive in Madhya Pradesh’s Satna allegedly due to contaminated blood transfusions at the district hospital during treatment for thalassaemia in December 2025.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.